Vildagliptin/metformin

Drug Profile

Vildagliptin/metformin

Alternative Names: Eucreas; Galvumet; Galvus Met; Galvusmet; Icandra; LMF 237; Metformin/vildagliptin; Zomarist

Latest Information Update: 29 Aug 2016

Price : $50

At a glance

  • Originator Novartis
  • Developer Hanmi Pharmaceutical; Novartis; UCB
  • Class Antihyperglycaemics; Biguanides; Cycloparaffins; Insulin sensitisers; Nitriles; Polycyclic bridged compounds; Pyrrolidines
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 29 Aug 2016 Launched for Type-2 diabetes mellitus in Bangladesh (PO) before August 2016
  • 15 Apr 2015 Vildagliptin/metformin is approved in Africa and is in phase-III development for Type-2 diabetes mellitus in Taiwan and USA
  • 09 Jul 2014 Novartis Korea and Hanmi Pharmaceutical agree to co-promote vildagliptin in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top